108 related articles for article (PubMed ID: 30668187)
41. Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review.
Fu J; Liu Y; Lin H; Wu B
Clin Drug Investig; 2018 Dec; 38(12):1167-1178. PubMed ID: 30232698
[TBL] [Abstract][Full Text] [Related]
42. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
43. [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ].
Groot MT; Ossenkoppele GJ; Kramer MH; van den Boom G; Huijgens PC; Uyl-de Groot CA
Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1460-5. PubMed ID: 12908349
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial.
Tan BK; Chua SS; Chen LC; Chang KM; Balashanker S; Bee PC
Support Care Cancer; 2020 Jul; 28(7):3237-3247. PubMed ID: 31734798
[TBL] [Abstract][Full Text] [Related]
45. Estimation of the prevalence and direct medical costs of chronic myeloid leukemia in the I.R. of Iran in the era of tyrosine kinase inhibitors.
Daroudi R; Mirzania M; Nikravanfard N; Sadighi S; Sedighi Z; Zendehdel K
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e416-e422. PubMed ID: 26990676
[TBL] [Abstract][Full Text] [Related]
46. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
[TBL] [Abstract][Full Text] [Related]
47. Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia.
Kropf P; Barnes G; Tang B; Pathak A; Issa JP
Leuk Lymphoma; 2016; 57(4):935-41. PubMed ID: 26480922
[TBL] [Abstract][Full Text] [Related]
48. The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment.
Eskazan AE; Soysal T
Leuk Lymphoma; 2015 May; 56(5):1554-5. PubMed ID: 25330444
[No Abstract] [Full Text] [Related]
49. Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.
Hirt C; Iannazzo S; Chiroli S; McGarry LJ; le Coutre P; Stenke L; Dahlén T; Lipton JH
Appl Health Econ Health Policy; 2019 Aug; 17(4):555-567. PubMed ID: 31168745
[TBL] [Abstract][Full Text] [Related]
50. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.
Breccia M; Luciano L; Latagliata R; Castagnetti F; Ferrero D; Cavazzini F; Trawinska MM; Annunziata M; Stagno F; Tiribelli M; Binotto G; Crisà E; Musto P; Gozzini A; Cavalli L; Montefusco E; Iurlo A; Russo S; Cedrone M; Rossi AR; Pregno P; Endri M; Spadea A; Molica M; Giglio G; Celesti F; Sorà F; Storti S; D'Addosio A; Cambrin GR; Isidori A; Sica S; Abruzzese E; Speccha G; Rosti G; Alimena G
Leuk Res; 2014 Oct; 38(10):1173-6. PubMed ID: 25047978
[TBL] [Abstract][Full Text] [Related]
51. The Development of a Web-Based, Patient-Centered Intervention for Patients With Chronic Myeloid Leukemia (CMyLife): Design Thinking Development Approach.
Ector GI; Westerweel PE; Hermens RP; Braspenning KA; Heeren BC; Vinck OM; de Jong JJ; Janssen JJ; Blijlevens NM
J Med Internet Res; 2020 May; 22(5):e15895. PubMed ID: 32412424
[TBL] [Abstract][Full Text] [Related]
52. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
Skrepnek GH; Ballard EE
Pharmacotherapy; 2005 Mar; 25(3):325-34. PubMed ID: 15843279
[TBL] [Abstract][Full Text] [Related]
53. A health economic simulation model for the clinical management of osteoporosis.
Jonsson E; Hansson-Hedblom A; Ljunggren Ö; Åkesson K; Spångeus A; Kanis JA; Borgström F
Osteoporos Int; 2018 Mar; 29(3):545-555. PubMed ID: 29196775
[TBL] [Abstract][Full Text] [Related]
54. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries.
Hofmarcher T; Cabrales Alin D; Linde C
Scand Cardiovasc J; 2018 Dec; 52(6):348-355. PubMed ID: 30457358
[TBL] [Abstract][Full Text] [Related]
55. Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations.
Reff MJ; Shillingburg A; Shah B; Elder C; Prescott H; Kennerly-Shah J
J Oncol Pharm Pract; 2020 Jan; 26(1):156-174. PubMed ID: 31354102
[TBL] [Abstract][Full Text] [Related]
56. [Progress of MM/CML treatment and medical economics].
Suzuki K
Rinsho Ketsueki; 2020; 61(6):587-597. PubMed ID: 32624530
[TBL] [Abstract][Full Text] [Related]
57. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
Lam MS; Cheung N
J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
[TBL] [Abstract][Full Text] [Related]
58. The rising prevalence of chronic myeloid leukemia in France.
Delord M; Foulon S; Cayuela JM; Rousselot P; Bonastre J
Leuk Res; 2018 Jun; 69():94-99. PubMed ID: 29734071
[TBL] [Abstract][Full Text] [Related]
59. Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia.
Daouphars M; Ouvry M; Lenain P; Rouvet J; Jardin F; Bubenheim M; Varin R
Pharmacotherapy; 2013 Feb; 33(2):152-6. PubMed ID: 23359430
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program.
Bourbeau J; Granados D; Roze S; Durand-Zaleski I; Casan P; Köhler D; Tognella S; Viejo JL; Dal Negro RW; Kessler R
Int J Chron Obstruct Pulmon Dis; 2019; 14():645-657. PubMed ID: 30936689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]